Syra Health Delivers Third Quarter 2024 Financial Results
Syra Health (NASDAQ: SYRA) reported Q3 2024 financial results with net revenue of $2.3 million, representing 42% growth year-over-year. The company's gross profit margin was 30%, and net loss narrowed to $417,535 ($0.06 per share), showing a 69% reduction compared to Q2 2024. Population Health revenues grew 36% while Healthcare Workforce services increased 54%. The company implemented significant cost-saving measures, reducing operating expenses by 37% quarter-over-quarter. With $2.7 million cash balance and no long-term debt, Syra Health aims to achieve profitability in 2025.
Syra Health (NASDAQ: SYRA) ha riportato i risultati finanziari del terzo trimestre 2024, con entrate nette di 2,3 milioni di dollari, che rappresentano una crescita del 42% rispetto all'anno precedente. Il margine di profitto lordo dell'azienda era del 30%, e la perdita netta si è ridotta a 417.535 dollari (0,06 dollari per azione), evidenziando una diminuzione del 69% rispetto al secondo trimestre 2024. I ricavi della Salute della Popolazione sono cresciuti del 36%, mentre i servizi per la forza lavoro sanitaria sono aumentati del 54%. L'azienda ha implementato misure significative di riduzione dei costi, riducendo le spese operative del 37% rispetto al trimestre precedente. Con un saldo di cassa di 2,7 milioni di dollari e senza debito a lungo termine, Syra Health punta a raggiungere la redditività nel 2025.
Syra Health (NASDAQ: SYRA) informó los resultados financieros del tercer trimestre de 2024, con ingresos netos de 2.3 millones de dólares, lo que representa un crecimiento del 42% en comparación con el año anterior. El margen de beneficio bruto de la compañía fue del 30%, y la pérdida neta se redujo a 417,535 dólares (0.06 dólares por acción), mostrando una reducción del 69% en comparación con el segundo trimestre de 2024. Los ingresos de Salud Poblacional crecieron un 36%, mientras que los servicios para la Fuerza Laboral Sanitaria aumentaron un 54%. La compañía implementó medidas significativas de ahorro de costos, reduciendo los gastos operativos en un 37% trimestre a trimestre. Con un saldo de efectivo de 2.7 millones de dólares y sin deuda a largo plazo, Syra Health tiene como objetivo alcanzar la rentabilidad en 2025.
Syra Health (NASDAQ: SYRA)는 2024년 3분기 재무 결과를 보고했으며, 순수익 230만 달러를 기록하여 전년 대비 42% 성장했습니다. 회사의 총 이익률은 30%이며, 순손실은 417,535달러(주당 0.06달러)로 줄어들어 2024년 2분기 대비 69% 감소하였습니다. 인구 건강 수익은 36% 성장했으며, 의료 인력 서비스는 54% 증가했습니다. 회사는 운영 비용을 분기별로 37% 절감하는 상당한 비용 절감 조치를 시행했습니다. 270만 달러의 현금 잔고와 장기 부채가 없는 Syra Health는 2025년 내에 수익성을 달성할 계획입니다.
Syra Health (NASDAQ: SYRA) a annoncé les résultats financiers du troisième trimestre 2024, avec des revenus nets de 2,3 millions de dollars, représentant une croissance de 42 % par rapport à l'année précédente. La marge bénéficiaire brute de l'entreprise était de 30 %, et la perte nette a été réduite à 417.535 dollars (0,06 dollar par action), montrant une réduction de 69 % par rapport au deuxième trimestre 2024. Les revenus de la Santé Communautaire ont augmenté de 36 %, tandis que les services pour la Force de Travail Sanitaire ont augmenté de 54 %. L'entreprise a mis en œuvre d'importantes mesures de réduction des coûts, réduisant les dépenses d'exploitation de 37 % d'un trimestre à l'autre. Avec un solde de 2,7 millions de dollars en liquidités et aucune dette à long terme, Syra Health vise à atteindre la rentabilité en 2025.
Syra Health (NASDAQ: SYRA) berichtete über die finanziellen Ergebnisse des dritten Quartals 2024 mit netto Einnahmen von 2,3 Millionen Dollar, was einem Wachstum von 42% im Vergleich zum Vorjahr entspricht. Die Bruttogewinnmarge des Unternehmens betrug 30% und der Nettoverlust verringerte sich auf 417.535 Dollar (0,06 Dollar pro Aktie), was eine 69%ige Reduzierung im Vergleich zum zweiten Quartal 2024 zeigt. Die Einnahmen im Bereich Population Health wuchsen um 36%, während die Dienstleistungen für das Gesundheitswesen um 54% zunahmen. Das Unternehmen führte bedeutende Maßnahmen zur Kostensenkung durch, wodurch die Betriebskosten im Quartalsvergleich um 37% gesenkt wurden. Mit einem Kassenbestand von 2,7 Millionen Dollar und ohne langfristige Schulden strebt Syra Health an, 2025 rentabel zu werden.
- Revenue growth of 42% year-over-year to $2.3 million
- 69% reduction in net loss compared to Q2 2024
- 37% reduction in operating expenses quarter-over-quarter
- Healthcare Workforce services revenue up 54% year-over-year
- Population Health revenue increased 36% year-over-year
- Gross margin improved from 17.8% in Q2 to 29.7% in Q3 2024
- $2.7 million cash balance with no long-term debt
- Net loss of $417,535 in Q3 2024
- Gross profit margin declined from 35% in Q3 2023 to 30% in Q3 2024
- Operating expenses increased 22.2% year-over-year
Insights
The Q3 results show promising operational improvements despite mixed financial metrics. Revenue growth of
Key positives include the
The launch of Syrenity represents a strategic pivot into the high-growth mental health tech sector, diversifying revenue streams beyond traditional services. The company's focus on ethical AI and clinically-proven practices positions it well in a competitive market. The
The milestone-based revenue model from digital health products like Syrabot, while causing short-term margin fluctuations, establishes recurring revenue potential. The combination of traditional healthcare services with tech-enabled solutions creates a compelling hybrid business model that could accelerate growth and improve margins as digital offerings scale.
Achieved Net Revenue of
Gross Margins Increased Following Shift in Operational Strategy
Net Loss Narrowed to
Aiming to Attain Profitability in 2025 through Targeted Revenue Growth and Cost-Efficiency Measures
Conference call will be held today, Tuesday, October 29th at 9:00 AM ET
Financial Highlights – 2024 Fiscal Third Quarter
Year over Year – Q3 2024 vs. Q3 2023
- Achieved Net Revenue of
$2.3 million 42% growth compared to 3Q23. - Population Health continues to grow, driven by demand for our public health services with revenues up
36% , alongside strong contributions from legacy Healthcare Workforce services with revenues up54% compared to 3Q23. - Gross profit margin was
30% in 3Q24, compared to35% in 3Q23, reflecting a milestone-based revenue recognition from our first digital health product in 3Q23. - Cash balance of
$2.7 million
Third Quarter 2024 vs. Second Quarter 2024
- Total Revenue increased
14.4% compared to 2Q24. - Gross profit margin was
29.7% in 3Q24 compared to17.8% in 2Q24, an increase of 1190 bps. - Net loss for 3Q24 showed a
69% reduction compared to 2Q24 demonstrating a consistent move toward profitability. - Net loss per share decreased to
$(0.06) $(0.21) - Total operating expenses in 3Q24 decreased
37% compared to 2Q24.
Recent Operational Highlights
- Successfully implemented cost-saving initiatives for sustainable impact
- Achieved a
37% overall reduction in operating expenses in 3Q24 compared to 2Q24. - SG&A expenses decreased by
37% in 3Q24 compared to 2Q24. - Realized a
30% decrease in salaries and benefits costs in 3Q24 compared to 2Q24.
- Achieved a
- Launched Syrenity, a mental health app built on clinically proven practices and ethical, compliant AI technology. Targeting a broad customer base—including large employers, academic institutions, health plans, and direct consumers—Syrenity taps into national and global markets. This product diversifies revenue streams and bolsters the Company's standing in the growing mental health tech sector, driving sustainable growth.
- Several government projects across multiple states are advancing into active implementation within high-margin business units. Launched the implementation of a four-year,
$5.8 million Indiana , with revenue expected to start in 4Q24. - Secured healthcare workforce contracts across several states, including
Delaware ,Florida , andKansas adding revenues to our legacy service line. - Completed a capital raise, generating gross proceeds of
$2.1 million
Management Commentary
Dr. Deepika Vuppalanchi, CEO of Syra Health, said, "We are excited to report year-over-year growth of
Additionally, our extensive cost-saving strategy has yielded significant reductions in expenses across the board with a
Q3 2024 Financial Results
Revenue for the quarter ended September 30, 2024, was
Gross profit margin was
Total operating expenses for the third quarter of 2024 were
Net loss for the third quarter of 2024 was
Total Revenue in the third quarter of 2024 was
Gross profit margin in the third quarter of 2024 was
Total operating expenses in the third quarter of 2024 decreased
Net loss for the third quarter of 2024 was
Cash on hand on September 30, 2024, was
Conference Call
Management will hold a conference call to discuss the fiscal year's financial results at 9:00 am ET on October 29, 2024.
Interested parties can listen via a live webcast, from the link available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q3-2024-earnings-call.
A replay will be available after the call, in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q3-2024-earnings-call.
ABOUT SYRA HEALTH
Syra Health leads the charge in addressing the toughest challenges in healthcare, from behavioral and mental health to population health, digital transformation, health education, and workforce development. Our technology-driven solutions focus on prevention, accessibility, and affordability, ensuring that every patient and provider gets the support they need. We proudly partner with payers, providers, life sciences organizations, academic institutions, and government entities to advance healthcare and improve outcomes. Learn more about our mission and services at www.syrahealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
SYRA HEALTH CORP. | ||||||||
September 30, | December 31, | |||||||
2024 | 2023 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 2,697,459 | $ | 3,280,075 | ||||
Accounts receivable, net | 884,445 | 1,060,634 | ||||||
Accounts receivable related party | - | 50,614 | ||||||
Other current assets | 482,990 | 389,787 | ||||||
Total current assets | 4,064,894 | 4,781,110 | ||||||
Property and equipment, net | 34,625 | 78,974 | ||||||
Right-of-use asset | 325,491 | 63,199 | ||||||
Total assets | $ | 4,425,010 | $ | 4,923,283 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 212,931 | $ | 462,991 | ||||
Accrued expenses | 309,606 | 198,978 | ||||||
Deferred revenue | 6,108 | - | ||||||
Current portion of operating lease liability, related party | 108,939 | 63,199 | ||||||
Notes payable | 240,221 | 184,904 | ||||||
Total current liabilities | 877,805 | 910,072 | ||||||
Non-current portion of operating lease liability, related party | 216,552 | - | ||||||
Total liabilities | 1,094,357 | 910,072 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity (deficit): | ||||||||
Preferred stock, | - | - | ||||||
Class A common stock, | 8,974 | 5,588 | ||||||
Convertible class B common stock, | 833 | 833 | ||||||
Additional paid-in capital | 11,640,642 | 9,071,745 | ||||||
Accumulated deficit | (8,319,796) | (5,064,955) | ||||||
Total stockholders' equity (deficit) | 3,330,653 | 4,013,211 | ||||||
Total liabilities and stockholders' equity (deficit) | $ | 4,425,010 | $ | 4,923,283 | ||||
SYRA HEALTH CORP. | ||||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net revenues | $ | 2,253,336 | $ | 1,581,344 | $ | 5,975,357 | $ | 3,748,943 | ||||||||
Cost of services | 1,585,038 | 1,026,803 | 4,777,765 | 2,919,087 | ||||||||||||
Gross profit | 668,298 | 554,541 | 1,197,592 | 829,856 | ||||||||||||
Operating expenses: | ||||||||||||||||
Salaries and benefits | 594,738 | 592,241 | 2,178,105 | 1,612,605 | ||||||||||||
Professional services | 153,803 | 58,875 | 489,839 | 424,379 | ||||||||||||
Research and development expenses | 34,821 | - | 590,263 | - | ||||||||||||
Selling, general and administrative expenses | 288,305 | 234,084 | 1,147,142 | 657,904 | ||||||||||||
Depreciation | 25,541 | 12,357 | 55,460 | 36,413 | ||||||||||||
Total operating expenses | 1,097,208 | 897,557 | 4,460,809 | 2,731,301 | ||||||||||||
Operating loss | (428,910) | (343,016) | (3,263,217) | (1,901,445) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest income | 13,641 | 2,820 | 18,448 | 2,826 | ||||||||||||
Interest expense | (2,266) | (14,180) | (10,072) | (44,449) | ||||||||||||
Total other income (expense) | 11,375 | (11,360) | 8,376 | (41,623) | ||||||||||||
Net loss | $ | (417,535) | $ | (354,376) | $ | (3,254,841) | $ | (1,943,068) | ||||||||
Weighted average common shares | 7,264,768 | 4,360,426 | 6,789,209 | 4,380,267 | ||||||||||||
Net loss per common share - basic and | $ | (0.06) | $ | (0.08) | $ | (0.48) | $ | (0.44) | ||||||||
SYRA HEALTH CORP. | ||||||||
2024 | 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (3,254,841) | $ | (1,943,068) | ||||
Adjustments to reconcile net loss to net cash used in operating | ||||||||
Depreciation | 55,460 | 36,413 | ||||||
Bad debt expense | - | 9,922 | ||||||
Common stock issued for services | 74,647 | - | ||||||
Non-cash lease expense | 63,199 | 90,162 | ||||||
Stock-based compensation, stock options | 28,486 | 3,669 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 176,189 | 136,324 | ||||||
Accounts receivable, related party | 50,614 | - | ||||||
Other current assets | 285,456 | 58,979 | ||||||
Accounts payable | (250,060) | 500,391 | ||||||
Accounts payable, related parties | - | 18,221 | ||||||
Deferred revenue | 6,108 | 141,644 | ||||||
Accrued expenses | 110,628 | 35,479 | ||||||
Operating lease liability | (63,199) | (90,162) | ||||||
Net cash used in operating activities | (2,717,313) | (1,002,026) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of property and equipment | (11,111) | (15,251) | ||||||
Net cash used in investing activities | (11,111) | (15,251) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Proceeds from sale of common stock and exercise of warrants | 2,469,150 | - | ||||||
Payment of deferred offering costs | - | (589,059) | ||||||
Proceeds received from line of credit | - | 300,000 | ||||||
Repayments on line of credit | - | (750,397) | ||||||
Proceeds received from advances, related party | - | 1,295,010 | ||||||
Repayments on advances, related party | - | (678,611) | ||||||
Repayments on notes payable | (323,342) | - | ||||||
Proceeds received from convertible notes payable | - | 1,455,000 | ||||||
Net cash provided by financing activities | 2,145,808 | 1,031,943 | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | (582,616) | 14,666 | ||||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF | 3,280,075 | 3,344 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 2,697,459 | $ | 18,010 | ||||
SUPPLEMENTAL INFORMATION: | ||||||||
Interest paid | $ | 10,072 | $ | 28,533 | ||||
Income taxes paid | $ | - | $ | - | ||||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
Initial recognition of right-of-use asset and lease liability | $ | 325,491 | $ | - | ||||
Prepaid asset financed with note payable | $ | 378,659 | $ | - | ||||
Contacts:
For Investor or Media Inquiries:
Priya Prasad
COO & CFO
Syra Health Corp.
463-345-8963
priyap@syrahealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-delivers-third-quarter-2024-financial-results-302289581.html
SOURCE Syra Health
FAQ
What was Syra Health's (SYRA) revenue growth in Q3 2024?
How much did Syra Health (SYRA) reduce its net loss in Q3 2024?
What is Syra Health's (SYRA) cash position as of September 30, 2024?
When does Syra Health (SYRA) aim to achieve profitability?
